Consonance Capital Management as of June 30, 2018
Portfolio Holdings for Consonance Capital Management
Consonance Capital Management holds 29 positions in its portfolio as reported in the June 2018 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Spectrum Pharmaceuticals | 9.4 | $146M | 7.0M | 20.96 | |
| Puma Biotechnology (PBYI) | 8.0 | $124M | 2.1M | 59.15 | |
| Pacira Pharmaceuticals (PCRX) | 7.8 | $120M | 3.8M | 32.05 | |
| Retrophin | 6.8 | $105M | 3.8M | 27.26 | |
| Vanda Pharmaceuticals (VNDA) | 5.7 | $88M | 4.6M | 19.05 | |
| Karyopharm Therapeutics (KPTI) | 5.2 | $81M | 4.8M | 16.99 | |
| Nevro (NVRO) | 4.9 | $75M | 943k | 79.85 | |
| Urogen Pharma (URGN) | 4.8 | $74M | 1.5M | 49.76 | |
| Corcept Therapeutics Incorporated (CORT) | 4.7 | $73M | 4.6M | 15.72 | |
| Exelixis (EXEL) | 4.5 | $69M | 3.2M | 21.52 | |
| United Therapeutics Corporation (UTHR) | 4.1 | $64M | 567k | 113.15 | |
| NuVasive | 3.7 | $57M | 1.1M | 52.12 | |
| Gw Pharmaceuticals Plc ads | 3.3 | $51M | 364k | 139.54 | |
| Verastem | 3.2 | $49M | 7.2M | 6.88 | |
| Pacific Biosciences of California (PACB) | 2.9 | $45M | 13M | 3.55 | |
| D Stemline Therapeutics | 2.8 | $44M | 2.7M | 16.05 | |
| Luminex Corporation | 2.7 | $43M | 1.4M | 29.53 | |
| Uniqure Nv (QURE) | 2.5 | $40M | 1.0M | 37.80 | |
| Vericel (VCEL) | 2.3 | $35M | 3.6M | 9.70 | |
| Savara (SVRA) | 2.0 | $31M | 2.7M | 11.32 | |
| Oxford Immunotec Global | 1.9 | $30M | 2.3M | 12.89 | |
| Adma Biologics (ADMA) | 1.2 | $19M | 4.2M | 4.51 | |
| Catalyst Pharmaceutical Partners (CPRX) | 1.2 | $19M | 6.0M | 3.12 | |
| Amarin Corporation (AMRN) | 1.0 | $15M | 5.0M | 3.09 | |
| Sesen Bio | 0.9 | $15M | 7.5M | 1.95 | |
| Ra Pharmaceuticals | 0.9 | $15M | 1.5M | 9.95 | |
| Cardiovascular Systems | 0.6 | $9.9M | 305k | 32.34 | |
| Biosante Pharmaceuticals (ANIP) | 0.6 | $9.5M | 143k | 66.80 | |
| Flexion Therapeutics | 0.4 | $5.6M | 217k | 25.85 |
